2Tutor O, Diaz MA, Ramirez M, et al. Loss of heterozygosity of p16 cor- relates with minimal residual disease at the end of the induction thera- py in non- high risk childhood B -cell precursor acute lymphoblastic leukemia[ J]. Leuk Res,2002,26(9) :817.
5Tokugawa T,Sugiharah,Tanit,et al. Modes of silencing of p16 in de- velopment of esophageal squamous cell carcinoma[ J]. Cancer Res , 2002,62(17) : 4938.
6Tada T, Watanabe T, Kazama S, et al. Reduced p16 expression corre- lates with lymphatic invasion in eoloreetal cancers [ J ]. Hepatogastro- enterology,2003,50(54 ) : 1756.
7Hussein MR, Abd-Elwahed SR, Abdulwahed AR. Alterations ofestro- gen receptors, progesterone receptors and c-erbB2 oncogeneprotein ex- pression in ductal carcinomas of the breast[J]. Cell Biol Int,2008,32 (6) :698.
8Lehr HA, Schaefer SC, Delaloye JF. Predictive value of Her2/neuex- pression/amplification for the targeted treatment of breast cancer[J]. Rev Med Suisse ,2009 ,5 (211) :1525.
10Chen H, Pimienta G, Gu Y, et al. Proteomic characterization of Her2 / neu -overexpressing breast cancer cells [ J ]. Proteomics, 2010, 10 (21) :3800.
9Mccready D R, Yong W S, Ng A K, et al. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and falsenegative rates [J]. J Natl Cancer Ins,2004,96(21 ) :873.
10Elisabetta R, Gerald F, Helena M, et al. Survival of young and older breast cancer patients in Geneva From 1990 to 2001 [J].Eur J Cancer,2005,41 (2) :1446.
4Bleicher R J, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer[J]. J Clin Oncol,2012,30(36) :4485-4492.
5Eralp Y,Ozluk DD, Yavuz E,et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple- negative breast cancer[J].Ann Oncol,2008,19(4) : 669-674.
6Umemura S,Yoshida S,Ohta Y,et al. Increased phosphoryl- ation of Akt in triple-negative breast cancer[J]. Cancer Sci, 2007,98(12): 1889-1892.
7Parikh RR, Yang Q, Higgins SA, et al. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CKI9 expression[J]. Int J Radiat Oncol Biol Phys,2008,70(1):35-42.
8Kashiwagi S, Yashiro M,Takashima T,et al. Significance of E-cadherin expression in triple-negative breast cancer[J]. Br J Cancer, 2010,103 : 249-255.
9Weng YR,Cui Y,Fang JY. Biological functions of cytokeratin 18 in cancer[J]. Mol Cancer Res,2012,10(4):485-493.
10Shetty S,Gokut S. Keratinization and its disorders[J]. Oman Med J,2012,27(5) :348-357.
